MD Biophysics Photobiomodulation Plasma (PPT)/ Very Small Embryonic like (VSEL) Antibody Marker Trend Analysis

This exploratory pilot study found that applying MD Biophysics photobiomodulation to autologous platelet-rich plasma was associated with directional increases in key Very Small Embryonic-like (VSEL) cell markers, suggesting a potential mechanism of stem cell activation that warrants further investigation in larger, controlled trials.

The Gist

Imagine your body as a massive, bustling construction site. When you get hurt or sick, the site needs repair crews to fix the damage. Usually, the site managers (your body's natural healing systems) send in the standard workers (regular cells). But sometimes, the damage is too big, or the standard workers are tired, and the site needs elite, super-versatile specialists who can turn into any type of worker needed—plumbers, electricians, or bricklayers.

In the scientific world, these elite specialists are called VSELs (Very Small Embryonic-like Stem Cells). They are tiny, rare, and incredibly powerful, but they often hide in the shadows of your body, waiting to be called into action.

This paper is like a field test report from a team trying to figure out how to wake up these sleeping specialists using a special tool: a light-based laser (Photobiomodulation) mixed with a concentrated healing serum made from your own blood (Platelet-Rich Plasma, or PRP).

Here is the story of what they found, broken down simply:

1. The Setup: The "Wake-Up Call" Experiment

The researchers, Dr. Dawn DeSylvia and Ian Mitchell, wanted to see if shining a specific kind of light on a sample of a patient's blood (mixed with their healing serum) could act like a loud alarm clock for these hidden stem cells.

• The Ingredients: They took blood from 18 volunteers, spun it to get the "healing serum" (PRP), and then shined their special "MD Biophysics Laser" on it.
• The Goal: To see if the light made the number of these "super-specialist" cells go up.
• The Test: They checked the blood before the light and after the light, looking for four specific "ID badges" (antibody markers) that prove a cell is one of these elite specialists.

2. The Results: A Trend, Not a Guarantee

Think of this study like a weather forecast based on only 18 days of data. It's too small to say "It will definitely rain tomorrow," but it can tell you, "It looks like the clouds are gathering."

• The Good News: For three out of the four "ID badges" they looked for, the number of cells went up after the light was applied.
  • Imagine a crowd of 18 people. For one badge, 12 people raised their hands saying, "More of us are here now!" For another, 10 people raised their hands.
  • This suggests the light might be successfully "waking up" or mobilizing these cells.
• The "Not Yet" News: Because the group was so small (only 18 people), the math didn't reach the strict "statistical significance" threshold usually required to prove a medical miracle. In science, this is like hearing a rumor that needs more witnesses before it becomes a confirmed fact.
• The Mixed Bag: One of the badges (CD45-CD34+) was a toss-up; about half the people saw an increase, and half saw a decrease. This tells the researchers they need to tweak their "recipe" to make it work better for everyone.

3. The "Why" It Matters: The Construction Site Analogy

Why do we care if these cells wake up?

• The Problem: As we age or get sick, our body's "construction site" gets stuck. The standard workers are tired, and the elite specialists are hiding. The site stays in a state of "repair mode" forever, leading to chronic pain, slow healing, or disease.
• The Solution: If this light therapy can successfully wake up the VSELs, it's like sending a fresh, energetic team of super-workers to the site.
  • They can fix a broken heart (cardiac issues).
  • They can clear up brain fog (neurological issues).
  • They can heal a wound that won't close.
  • The paper mentions that in real-world clinical use (outside this specific lab test), patients have seen improvements in vision, blood sugar, and even heart function.

4. The Takeaway: A Promising Clue, Not the Final Answer

The authors are very honest: This isn't the final proof yet. It's a "pilot study," which is basically a dress rehearsal.

• What they learned: The light seems to work. The trend is pointing in the right direction. The "recipe" (the specific light frequency and blood collection method) is starting to get refined.
• What's next: They need to test this on a much larger group (about 48 people) to prove it works for sure. They also want to check if the light wakes up other types of helpers (like MUSE cells) and to measure exactly how the cells are talking to each other.

The Bottom Line

Imagine you have a flashlight that you think can wake up a sleeping army of tiny repair bots inside your body. This paper is the first time someone shined that flashlight on a small group of people and said, "Hey, look! The bots are starting to stir and move around!"

It's not a guarantee that the flashlight works for everyone yet, but it's a very exciting clue that suggests light might be a powerful key to unlocking our body's own ability to heal itself. The researchers are now building a bigger, better flashlight to test this theory on a larger scale.

Technical Summary

1. Problem Statement and Background

• Context: Photobiomodulation (PBM) therapy and Platelet-Rich Plasma (PRP) are established regenerative modalities. PBM promotes cellular repair via mitochondrial activation, while PRP delivers growth factors. Very Small Embryonic-Like stem cells (VSELs) are rare, pluripotent stem cells in adult tissues hypothesized to drive regeneration.
• The Gap: While PBM and PRP are often used clinically in combination, the biological mechanism regarding whether PBM activates or expands VSEL populations within PRP is not well-characterized. Previous literature lacks definitive peer-reviewed evidence linking light/frequency modalities directly to VSEL expansion. Furthermore, prior studies often relied on single markers and failed to confirm the presence of live, actively dividing cells.
• Objective: This exploratory pilot study aimed to determine if applying the MD Biophysics Laser to autologous PRP results in measurable changes in VSEL-associated antibody markers and to identify directional trends to inform future controlled studies.

2. Methodology

• Study Design: An exploratory, uncontrolled pilot study conducted across 7 test dates (July 2024 – February 2025).
• Participants: 18 individuals (11 female, 7 male; ages 32–90) recruited from Dr. Dawn DeSylvia's practice. Participants provided informed consent and donated peripheral blood.
• Intervention:
  • Autologous PRP was prepared from participant blood.
  • Samples were analyzed at baseline (Pre) and immediately after application of the MD Biophysics Laser (Post).
  • The laser utilized a standardized "wellness frequency" set with adjustable frequencies and pulse width modulation (PWM) for depth-specific energy delivery.
  • The protocol was iteratively refined across the 7 sessions based on observed trends.
• Analytical Techniques:
  • Flow Cytometry: Conducted at the UCLA Flow Cytometry Laboratory.
  • Markers Assessed: Four VSEL-associated antibody markers were quantified:
    1. CD45⁻CD34⁺: Hematopoietic progenitor phenotype.
    2. CXCR4⁺: Chemokine receptor associated with stem cell homing/mobilization.
    3. CD133⁺: Primitive progenitor cell marker.
    4. SSEA-4⁺: Pluripotency marker distinguishing VSELs from MUSE cells.
  • Viability Check: Ki-67 was added in the final round to confirm the presence of actively dividing (proliferative) cells.
• Statistical Analysis:
  • Descriptive statistics (Mean, Median, SD).
  • Paired comparisons (Pre vs. Post) using the Wilcoxon Signed-Rank Test (non-parametric) due to small sample size ($n=18$).
  • Effect size calculation using Cohen's d (paired).
  • No control group was used; analysis focused on directional trends and paired differences.

3. Key Results

• Directional Trends:
  • CXCR4⁺: 12/18 sessions showed an increase (Median change: +0.109%).
  • CD133⁺: 10/18 sessions showed an increase (Median change: +0.060%).
  • SSEA-4⁺: 9/18 sessions showed an increase (Median change: +0.001%).
  • CD45⁻CD34⁺: Showed a near-equal split (8 increased, 9 decreased), with a slight group-level decrease.
• Statistical Significance:
  • None of the markers reached statistical significance ($p < 0.05$) due to the limited sample size and high inter-patient variability.
  • P-values: CXCR4⁺ ($p=0.408$), CD133⁺ ($p=0.344$), SSEA-4⁺ ($p=0.962$), CD45⁻CD34⁺ ($p=1.000$).
• Effect Sizes:
  • Cohen's d values were generally negligible to small:
    • CD133⁺: 0.242 (Small)
    • CD45⁻CD34⁺: 0.076 (Negligible)
    • CXCR4⁺: 0.053 (Negligible)
    • SSEA-4⁺: -0.116 (Negligible)
• Viability: Ki-67 positivity confirmed that the detected cells were viable and actively dividing.

4. Key Contributions

• Multi-Marker Approach: Unlike previous studies that often used a single marker (CD45⁻CD34⁺), this study utilized a 4-marker panel to provide a more comprehensive profile of VSEL populations.
• Viability Confirmation: The inclusion of Ki-67 provided evidence that the observed marker changes represented live, proliferating cells, addressing a gap in previous literature.
• Protocol Optimization: The study served as an iterative pilot, testing various collection kits and laser parameters to identify a protocol that yields consistent directional trends, laying the groundwork for a formalized clinical trial.
• Hypothesis Generation: Despite the lack of statistical significance, the consistent directional increases in CXCR4⁺ and CD133⁺ provide a data-driven basis for powering future confirmatory studies.

5. Significance and Future Directions

• Clinical Relevance: The findings suggest a potential mechanism of action for PBM-PRP therapies involving stem cell activation or mobilization. This aligns with clinical observations of improved healing, metabolic regulation, and neurocognitive function in patients treated with this modality.
• Limitations: The study is limited by small sample size ($n=18$), lack of a control group, and high variability in baseline values (particularly for CXCR4⁺). The authors explicitly state these are hypothesis-generating findings, not confirmatory.
• Future Study Requirements:
  • Sample Size: To detect a medium effect size (Cohen's $d=0.5$) with 80% power and a Bonferroni-corrected alpha ($0.0125$ for 4 markers), a future study requires approximately 48 participants.
  • Design: A randomized, controlled trial with matched baselines.
  • Expanded Metrics: Future studies should include SSEA-3 (for MUSE cells), cytokine/growth factor profiling, and correlation with clinical outcomes.

Conclusion: This pilot study provides preliminary evidence that MD Biophysics laser application to PRP is associated with directional increases in specific VSEL markers (CXCR4⁺, CD133⁺, SSEA-4⁺) and the presence of proliferating cells. While statistically underpowered, the results support the feasibility of a larger, controlled trial to validate the biological mechanism of PBM-induced stem cell activation.